Evidence map›Paper›PMID 36883080›Full record

ArticleCureus2023

Outcome of Intra-articular Injection of Total Stromal Cells and Platelet-Rich Plasma in Primary Knee Osteoarthritis: A Randomized Clinical Trial.

Moshiur R Khasru, Md Abu B Siddiq, Talukder Agm Zakaria N Jubery, Tangila Marzen, Ashraful Hoque, Akm Zahir Ahmed, Masuda Begum, Fazle R Chowdhury, Abul Khair M Salek, Md Moniruzzaman Khan

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Stem cell injections for osteoarthritis of the knee.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Moshiur R KhasruPhysical Medicine and Rehabilitation, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD.
Md Abu B SiddiqPhysical Medicine and Rehabilitation, Brahmanbaria Medical College, Brahmanbaria, BGD.
Talukder Agm Zakaria N JuberyBurn and Plastic Surgery, Dhaka Medical College Hospital, Dhaka, BGD.
Tangila MarzenAnatomy, Shaheed Suhrawardy Medical College Hospital, Dhaka, BGD.
Ashraful HoqueBlood Transfusion, Sheikh Hasina National Institute of Burn & Plastic Surgery, Dhaka, BGD.
Akm Zahir AhmedMusculoskeletal Sonography, Module General Hospital, Dhaka, BGD.
Masuda BegumHematology, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD.
Fazle R ChowdhuryInternal Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD.
Abul Khair M SalekPhysical Medicine and Rehabilitation, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD.
Md Moniruzzaman KhanPhysical Medicine and Rehabilitation, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD.
Bangabandhu Sheikh Mujib Medical University · BDShaheed Suhrawardy Medical College · BDUniversity of South Wales · GBDhaka Medical College and Hospital · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMesenchymal stem cell (MSC) therapy appeared promising in knee osteoarthritis (OA). We examined if a single intra-articular (IA) autologous total stromal cells (TSC) and platelet-rich plasma (PRP) injection improved knee pain, physical function, and articular cartilage thickness in knee OA.

methodsThe study was performed in the physical medicine and rehabilitation department of Bangabandhu Shaikh Mujib Medical University, Dhaka, Bangladesh. Knee OA was diagnosed according to the American College of Rheumatology criteria and randomly assigned to treatment (received TSC and PRP) and control groups. Kallgreen-Lawrance (KL) scoring system was used to grade primary knee OA. The Visual Analogue Scale (VAS, 0-10 cm) for pain, WOMAC (Western Ontario and McMaster Universities Arthritis Index) for physical function, and medial femoral condylar cartilage (MFC) thickness (millimeters) under ultrasonogram (US) were documented and compared between groups before and after treatment. Statistical Package analyzed data for Social Scientists (SPSS 22.0; IBM Corp, Armonk, NY) was used for data analysis. Pre- and post-intervention outcomes were measured using the Wilcoxon-sign test, whereas Mann-Whitney U-test calculated the difference between groups; a p-value <0.05 was considered statistically significant.  Result: In the treatment group, 15 received IA-TSC and PRP preparation, and in the control group, 15 patients received no injection, but quadricep muscle-strengthening exercise. There was no significant difference between groups regarding VAS for pain, WOMAC physical function, and cartilage thickness before starting the treatment and two weeks after intervention. VAS for pain and WOMAC physical function scores improved profoundly in the treatment group after 12 and 24 weeks of intervention; the pain and physical function scores difference between groups was also significant. However, significant mean femoral cartilage thickness was not changed until the end of 24 weeks (U=175.00, p=0.009 two-tailed and U= 130.00, p=0.016 two-tailed, respectively, for right and left knee).

conclusionSingle TSC and PRP injection reduces knee pain and improves physical function and cartilage thickness in knee OA. While pain and physical function improvement happen earlier, cartilage thickness change takes more time.

Indexed as

knee osteoarthritismesenchymal stem cellosteoarthritissingle intra-articular injectiontotal-stromal-cells (tost)

Identifiers

PMID36883080
PMCPMC9985905
OpenAlexW4319078498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.